Drug reaction with eosinophilia and systemic symptoms (DRESS) and multiple organ dysfunction syndrome (MODS): one more reason for a new effective treatment against leishmaniasis

Cuestas, Daniel; Forero, Yency; Galvis, Ingrid; Peñaranda, Elkin; Cortés, Carolina Ivette; Motta, Adriana; Mora, Sergio; Pérez, Carlos; Velásquez, Óscar; Puentes, José Antonio

doi:10.1111/ijd.14126

Cited by 7 publications

(10 citation statements)

References 64 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A notable but rare condition is DRESS (drug reaction with eosinophilia and systemic symptoms) syndrome. It is manifested by skin lesions and possible life-threatening systemic symptoms [ 49 ]. DRESS syndrome was first described in 1930 [ 49 ] but the current terminology and first classification criteria of this condition were established in 1996 [ 50 ].…”

Section: Causes Of Secondary Hypereosinophiliamentioning

confidence: 99%

“…It is manifested by skin lesions and possible life-threatening systemic symptoms [ 49 ]. DRESS syndrome was first described in 1930 [ 49 ] but the current terminology and first classification criteria of this condition were established in 1996 [ 50 ]. Skin lesions are the most characteristic manifestations.…”

Section: Causes Of Secondary Hypereosinophiliamentioning

confidence: 99%

“…The lesions are usually located on the skin above the diaphragm, sometimes also on mucous membranes. Systemic symptoms include fever, lymphadenopathy, hepatic failure, thyroiditis, myositis, myocarditis, pericarditis, uveitis, polyneuropathy, encephalitis and meningitis [ 49 ]. Eosinophils and atypical lymphocytes are visible in peripheral blood film.…”

Section: Causes Of Secondary Hypereosinophiliamentioning

confidence: 99%

“…The most common causes of the DRESS syndrome are taking antiepileptic drugs, sulfonamides and antivirals. Other described medicines include allopurinol, proton pump inhibitors, strontium ranelate and minocycline [ 49 , 51 ]. The pathogenesis of the disease has not been fully elucidated.…”

Section: Causes Of Secondary Hypereosinophiliamentioning

confidence: 99%

See 3 more Smart Citations

The challenge of diagnosing and classifying eosinophilia and eosinophil disorders: A review

Szymczyk,

Jaworski,

Podhorecka

2024

cejoi

View full text Add to dashboard Cite

Eosinophilia is a feature of multiple conditions, both hematologic and non-hematologic, and may be associated with organ damage. The pathogenesis of eosinophilia can follow two distinct pathways. Primary eosinophilia is caused by a cell-intrinsic mechanism originating from clonal expansion of eosinophils through acquisition of a somatic mutation, such as FIP1L1-PDGFRA. In recent years, great progress has been made in the field of pathogenesis and molecularly targeted therapy of neoplastic eosinophilia. The diagnostic procedure should include, among other things, morphologic analysis of blood and bone marrow samples, cytogenetics and fluorescence in situ-hybridization tests to detect evidence of an acute or chronic myeloid or lymphoid disorder. Secondary eosinophilia follows a cell-extrinsic mechanism as a response to exogenous cytokines. In most clinical cases, peripheral blood eosinophilia is reactive and typically associated with non-hematological disorders such as infections, allergic conditions, connective tissue disorders, vasculitis, malignancy, or endocrinopathies. Nonetheless, the cause of most cases of hypereosinophilic syndrome remains unknown. In this article, we present a short review focused on differential diagnosis of eosinophilia and eosinophilic disorders. The diagnosis of eosinophilia is a challenge for physicians; thus this review may be useful in clinical practice.

show abstract

Section: Causes Of Secondary Hypereosinophiliamentioning

confidence: 99%

Section: Causes Of Secondary Hypereosinophiliamentioning

confidence: 99%

Section: Causes Of Secondary Hypereosinophiliamentioning

confidence: 99%

Section: Causes Of Secondary Hypereosinophiliamentioning

confidence: 99%

See 2 more Smart Citations

The challenge of diagnosing and classifying eosinophilia and eosinophil disorders: A review

Szymczyk,

Jaworski,

Podhorecka

2024

cejoi

View full text Add to dashboard Cite

show abstract

“…However, these drugs present with several drawbacks such as the expensive cost, limited cure rates, recurrences and numerous side‐effects including nauseas, vomiting, skin rash and arthralgias. Even severe adverse effects such as nephropathy, hepatic toxicity and cardiac arrhythmias may occur during the systemic administration 7‐9 . On top of this, parasites are able to become resistant to the antimonials whose efficacy is diminishing over time 10 .…”

Section: Introductionmentioning

confidence: 99%

Evidence supporting the enhanced efficacy of pentavalent antimonials with adjuvant therapy for cutaneous leishmaniasis: a systematic review and meta‐analysis

Husein‐ElAhmed

Gieler

Steinhoff

2020

Acad Dermatol Venereol

View full text Add to dashboard Cite

Cutaneous leishmaniasis (CL) is one of the major neglected disease worldwide. Although many drugs have been used, the pentavalent antimonials (PA) remain as the first-line choice despite their toxicity and limited efficacy. The combination of two drugs has risen as a potential alternative to increase the cure rate while lowering the side-effects caused by pentavalent antimonials (PA). The objective of this study was to critically review and appraise the potential synergism of the adjuvant therapies of PA with other drugs/interventions previously used in the literature. We carried out a search of literature from PubMed, MEDLINE, Embase, Cochrane and clinicaltrials.gov. Articles that described a two-arm or threearm design in which one of the arms consisted in a combination of a drug/intervention with intralesional or systemic PA were selected. The primary outcome was proportion of complete clearance of the lesions defined as complete re-epithelization and/or negative direct smear. Our literature search identified 554 references. Thirty-one records with a total sample size of 2668 participants met the eligibility criteria. The studies investigated the association of PA with the following: cryotherapy (five studies), allopurinol, imiquimod, pentoxifylline (four studies each), trichloroacetic acid 50% (three studies) and other additional interventions (eleven studies). Overall, the combined therapy of PA with a supplementary intervention was superior to PA monotherapy (RR: 1.23 95% CI: 1.11-1.35, I 2 = 64%). In association with PA, the comparator-specific stratified analysis showed that cryotherapy (RR: 1.50 95% CI: 1.25-1.81, I 2 = 57%) and allopurinol (RR: 1.70 95% CI: 1.37-2.12, I 2 = 28%) were superior to PA in monotherapy. On the contrary, the combined therapy with imiquimod (RR: 1.08 95% CI: 0.88-1.32, I 2 = 40%) and pentoxifylline (RR: 1.14 95% CI: 0.94-1.40, I 2 = 41%) revealed a non-significant result. The application of TCA along with PA did not show significant differences in the clearance rate, although it was close to it (RR: 1.31 95% CI: 0.99-1.73, I 2 = 84%). The present work represents an attempt to find new and reliable treatment modalities to enhance the efficacy based on the adjuvant therapy of pre-existing drugs/interventions with PA. According to our results, the combination of allopurinol-PA is the most effective adjuvant therapy. The application of cryotherapy and TCA stand as useful and encouraging supplementary interventions. The combination of imiquimod-PA and pentoxifylline adds no additional benefit. The results of this work may be helpful in devising and modifying the current guidelines for CL which face major remaining evidence gaps. Triple therapies consisting in cryotherapy-PA-TCA or allopurinol-PA-cryotherapy or allopurinol-PA-TCA can represent promising treatments yet to be confirmed in future trials.

show abstract

Meglumine-antimonate

2018

Reactions Weekly

View full text Add to dashboard Cite

Drug reaction with eosinophilia and systemic symptoms (DRESS) and multiple organ dysfunction syndrome (MODS): one more reason for a new effective treatment against leishmaniasis

Cited by 7 publications

References 64 publications

The challenge of diagnosing and classifying eosinophilia and eosinophil disorders: A review

The challenge of diagnosing and classifying eosinophilia and eosinophil disorders: A review

Evidence supporting the enhanced efficacy of pentavalent antimonials with adjuvant therapy for cutaneous leishmaniasis: a systematic review and meta‐analysis

Meglumine-antimonate

Contact Info

Product

Resources

About